New shares subscribed for in Optomed Plc’s directed share issue have been registered in the Finnish Trade Register

Optomed Plc has registered 1,760,000 new shares from a directed share issue on 12 December 2025, bringing total shares outstanding to 21,453,297 (22,042 in treasury); the new shares carry dividend and other shareholder rights as of registration and will be admitted to trading on Nasdaq Helsinki on 15 December 2025. The filing completes the administrative step following the directed issue and increases Optomed’s share base as the Finnish medtech company continues to scale its handheld fundus cameras and AI-driven eye screening solutions.

Analysis

Optomed Plc registered 1,760,000 new shares from a directed share issue in the Finnish Trade Register on 12 December 2025, bringing total issued shares to 21,453,297 of which 22,042 are treasury shares; the new shares carry dividend and other shareholder rights as of registration and will be admitted to trading on Nasdaq Helsinki on 15 December 2025. The announcement is an administrative completion of the directed issue rather than a change in commercial guidance, and the company confirmed trading and shareholder rights timing but did not disclose issue price or gross proceeds in this release.

The share count prior to the registration was 19,693,297, so the newly registered shares represent an approximate 8.9% increase relative to the prior base and about 8.2% of the enlarged share capital. Because this was a directed share issue, allocation may have been strategic or targeted; absent price and use-of-proceeds detail, investors should treat potential dilution to EPS and ownership as the primary quantifiable impact.

Market signals attached to the release are neutral with a modest market-impact score (0.12), suggesting limited immediate market disruption, but the key near-term variables that will determine investor reaction are the issuance price, receipts deployment (R&D, commercial expansion, or working capital), and liquidity on 15 December when shares begin trading.

Key Decisions for Investors

• Reassess position sizing to reflect an ~8.9% increase in the pre-issue share base and model potential EPS dilution under simple per-share metrics
• Monitor Nasdaq Helsinki trading on 15 December for price reaction and incremental liquidity before initiating material new positions
• Request or wait for company disclosure on the issue price and detailed use of proceeds; avoid making large directional bets until deployment is confirmed
• If follow-up disclosures confirm proceeds are earmarked for growth initiatives in handheld fundus cameras and AI, consider adding on sustained weakness while maintaining a watch on execution milestones